- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 21.04. | Alto Neuroscience launches phase 2b trial for depression drug | 3 | Investing.com | ||
| 21.04. | Alto Neuroscience, Inc.: Alto Neuroscience Initiates Phase 2b Trial of ALTO-207 in Treatment-Resistant Depression | 320 | Business Wire | - Phase 2b closely resembles PAX-D study design, which demonstrated an effect size for pramipexole more than two times larger than approved TRD therapies - - Trial design and MADRS primary endpoint... ► Artikel lesen | |
| ALTO NEUROSCIENCE Aktie jetzt für 0€ handeln | |||||
| 06.04. | H.C. Wainwright reiterates Alto Neuroscience stock rating at buy | 1 | Investing.com | ||
| 06.04. | H.C. Wainwright hält an "Buy"-Rating für Alto Neuroscience fest | 1 | Investing.com Deutsch | ||
| 01.04. | Alto Neuroscience's ALTO-101 misses primary endpoint in trial | 4 | Investing.com | ||
| 01.04. | Alto Neuroscience, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 18.03. | Stifel reiterates Buy on Alto Neuroscience stock, $33 target | 1 | Investing.com | ||
| 16.03. | Jefferies raises Alto Neuroscience stock price target on pipeline | 1 | Investing.com | ||
| 16.03. | Alto Neuroscience Shares Rise 9% After FY25 Results And $120 Mln Private Placement | - | RTTNews | ||
| 16.03. | Alto Neuroscience: $120 Million Raised To Advance Treatment-Resistant Depression Drug Candidate | 2 | pulse2.com | ||
| 16.03. | Alto Neuroscience announces $120M private placement financing | 1 | Seeking Alpha | ||
| 16.03. | Alto Neuroscience, Inc. - S-8, Securities to be offered to employees in employee benefit plans | - | SEC Filings | ||
| 16.03. | Alto Neuroscience GAAP EPS of -$2.19 beats by $0.06 | 2 | Seeking Alpha | ||
| 16.03. | Alto Neuroscience, Inc. - 10-K, Annual Report | - | SEC Filings | ||
| 16.03. | Alto Neuroscience, Inc. - 8-K, Current Report | - | SEC Filings | ||
| 13.02. | Alto Neuroscience completes enrollment in schizophrenia drug trial | 2 | Investing.com | ||
| 14.01. | Alto Neuroscience erhält US-Patent für Methode zur Depressionsbehandlung | 4 | Investing.com Deutsch | ||
| 14.01. | Alto Neuroscience receives patent for depression treatment method | 2 | Investing.com | ||
| 05.01. | Chardan Capital Markets assumes coverage on Alto Neuroscience stock with Buy rating | 1 | Investing.com | ||
| 17.11.25 | This Alto Neuroscience Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Monday | 1 | Benzinga.com |
1 2 Weiter >>
27 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 86,55 | -0,69 % | Biotech-Player: Zelltherapie als Comeback-Story im Milliardenmarkt. Neue Ideen nach Corona von BioNTech, Qiagen und Biotech AG | ||
| AMGEN | 288,45 | -0,53 % | Did Amgen's Subsidiary Manipulate Data To Secure Tavneos Approval? | THOUSAND OAKS (dpa-AFX) - It takes 10-15 years and billions of dollars for a pharma company to bring a drug to the market. Now imagine that after years of effort, time, and investment, a company... ► Artikel lesen | |
| NOVAVAX | 6,650 | -1,77 % | Novavax (NVAX) Dips More Than Broader Market: What You Should Know | ||
| BIOGEN | 166,48 | +6,34 % | Ihre wichtigsten Termine: Alphabet, Meta, Microsoft, Amazon, Ebay, Biogen & Mercedes-Benz legen Zahlen vor | © Foto: Dall-EGut geplant in den Tag. Mit dem wO-Tagesausblick haben Sie die wichtigsten Termine im Blick und starten bestens vorbereitet in den neuen Handelstag.Unternehmenstermine 06:45 Uhr, Schweiz:... ► Artikel lesen | |
| VIKING THERAPEUTICS | 26,800 | -3,07 % | Viking Therapeutics, Inc.: Viking Therapeutics Announces Completion of Enrollment in Phase 3 VANQUISH-2 Trial of VK2735 | 78-Week Study Evaluating Subcutaneous VK2735 in Adults with Obesity and Type 2 Diabetes
SAN DIEGO, March 26, 2026 /PRNewswire/ -- Viking Therapeutics, Inc. (Viking)... ► Artikel lesen | |
| MAINZ BIOMED | 0,459 | -7,83 % | Quantum Cyber N.V. - 8-K, Current Report | ||
| INTELLIA THERAPEUTICS | 10,540 | -6,56 % | Intellia Therapeutics prices $180M stock offering at discount | ||
| TEMPUS AI | 42,920 | -1,67 % | Tempus AI Stock Before Q1 Earnings Release: To Buy or Not to Buy? | ||
| BIOCRYST PHARMACEUTICALS | 7,652 | +1,16 % | BioCryst Pharmaceuticals, Inc.: BioCryst Appoints Sandeep M. Menon Chief Research and Development Officer | - Experienced R&D leader with a track record of advancing innovative therapies from early development to global approval - RESEARCH TRIANGLE PARK, N.C., April 06, 2026 (GLOBE NEWSWIRE) -- BioCryst... ► Artikel lesen | |
| BIOMARIN PHARMACEUTICAL | 45,730 | +0,46 % | BioMarin Pharmaceutical Inc.: BioMarin Completes Acquisition of Amicus Therapeutics | Acquisition Adds Galafold® (migalastat) for Fabry Disease and Pombiliti® (cipaglucosidase alfa-atga) + Opfolda® (miglustat) for Pompe Disease to BioMarin's Commercial... ► Artikel lesen | |
| SAREPTA THERAPEUTICS | 17,760 | -1,33 % | Mesoblast: Neue Fantasie durch Technologie - und ein wachsender Zielmarkt | ||
| EXELIXIS | 38,235 | -0,39 % | Exelixis-Aktie: Blockbuster-Kandidat Zanzalintinib vor Zulassung | Auf der Suche nach wachstumsstarken Biotech-Unternehmen mit angemessener Bewertung rückt Exelixis ins Blickfeld. Der Onkologiespezialist ist profitabel, verfügt über mehrere in den USA vermarktete Therapien... ► Artikel lesen | |
| PACIFIC BIOSCIENCES OF CALIFORNIA | 1,240 | -7,84 % | PacBio & Lucid Genomics Partner to Boost Data Analysis, Stock Up | ||
| CARDIOL THERAPEUTICS | 1,102 | -6,29 % | Cardiol Therapeutics Inc.: Cardiol Therapeutics Expands U.S. MAVERIC Phase III Trial Network to Address Growing Interest in the Pivotal Program | Leading enrolling centers include Cleveland Clinic, three major campuses of the Mayo Clinic, Northwestern University, Massachusetts General Hospital, Columbia... ► Artikel lesen | |
| VAXART | 0,380 | 0,00 % | Vaxart adds James Breitmeyer to board of directors |
ALTO NEUROSCIENCE INC gehört der Branche Biotechnologie an. Der aktuelle Kurs liegt bei 23,990 Euro und damit -1,68 % im Minus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ALTO NEUROSCIENCE INC finden Sie auf Wallstreet Online.